Humacyte Ownership | Who Owns Humacyte?

Overview Forecast RevenueFinancials Chart Transcripts

Humacyte Ownership Summary

Humacyte is owned by 37.70% institutional investors, 7.29% insiders, and 55.01% retail investors. Blackrock is the largest institutional shareholder, holding 6.60% of HUMA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.86% of its assets in Humacyte shares.

HUMA Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Humacyte	37.70%	7.29%	55.01%
Sector	Healthcare Stocks	244.37%	12.11%	-156.48%
Industry	Biotech Stocks	379.01%	11.75%	-290.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	7.14M	6.60%	$34.27M
Vanguard group	8.42M	5.32%	$8.09M
Vanguard capital management	10.11M	5.11%	$7.88M
Antipodes partners	10.10M	5.11%	$7.88M
Alyeska investment group	6.02M	3.04%	$4.70M
Davidson kempner capital management lp	5.00M	2.53%	$3.90M
Blackrock funding, inc. /de	4.84M	2.45%	$3.78M
Great point partners	3.75M	1.90%	$2.93M
Ubs group	2.84M	1.44%	$2.22M
Aqr capital management	2.60M	1.31%	$2.03M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lion point capital, lp	650.00K	2.43%	$507.26K
Great point partners	3.75M	0.55%	$2.93M
Scientech research	284.00K	0.18%	$221.64K
Wealth effects	693.92K	0.15%	$541.53K
Antipodes partners	10.10M	0.14%	$7.88M
Stonepine capital management	231.30K	0.08%	$180.51K
Imprint wealth	16.36K	0.05%	$12.77K
Gsa capital partners llp	1.01M	0.05%	$785.00K
Aster capital management (difc)	422.36K	0.05%	$329.61K
Davidson kempner capital management lp	5.00M	0.05%	$3.90M

Top Buyers

Holder	Shares	% Assets	Change
Alyeska investment group	6.02M	0.01%	6.02M
Davidson kempner capital management lp	5.00M	0.05%	5.00M
Antipodes partners	10.10M	0.14%	4.38M
Vanguard capital management	10.11M	0.00%	2.95M
Blackrock	7.14M	0.00%	2.35M

Top Sellers

Holder	Shares	% Assets	Change
Blackrock funding, inc. /de	4.84M	0.00%	-7.48M
Heights capital management	-	-	-4.03M
Ra capital management	-	-	-3.31M
State street	842.54K	-	-2.20M
Aigh capital management	-	-	-2.16M

New Positions

Holder	Shares	% Assets	Change	Value
Alyeska investment group	6.02M	0.01%	6.02M	$4.70M
Davidson kempner capital management lp	5.00M	0.05%	5.00M	$3.90M
Sixth street partners management company	1.35M	0.00%	1.35M	$1.06M
Hrt financial lp	1.09M	0.00%	1.09M	$850.00K
Hbk investments l p	790.00K	0.01%	790.00K	$616.52K

Sold Out

Holder	Change
Org partners	-10.00
Principal securities	-15.00
Transce3nd	-16.00
Burkett financial services	-18.00
Newbridge financial services group	-60.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	171	3.64%	74,595,401	26.40%	37	4.24%	97	10.23%	38	18.75%
Mar 31, 2026	163	7.24%	59,001,451	6.66%	37	3.06%	88	14.29%	31	-13.89%
Dec 31, 2025	100	-32.89%	41,097,732	-10.40%	25	2.98%	52	-10.34%	19	-57.78%
Sep 30, 2025	91	-41.67%	30,080,405	-43.82%	19	1.63%	36	-64.36%	27	12.50%
Jun 30, 2025	163	-6.86%	56,940,940	-6.40%	36	1.71%	104	8.33%	26	-29.73%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	7.72M	2.86%	2.42M
Vanguard Morn Total Stk Mkt Idx Investor	7.72M	2.86%	2.42M
Vanguard MStar Total Stk Mkt Idx Invest	7.72M	2.78%	-
iShares Russell 2000 ETF	3.97M	2.06%	36.71K
SPDR® S&P Biotech ETF	2.26M	1.43%	5.04K
Vanguard Institutional Extnd Mkt Idx Tr	2.12M	0.76%	-
iShares Biotechnology ETF	1.79M	0.66%	-5.45K
Fidelity Small Cap Index	1.65M	0.61%	67.07K
Nuveen Quant Small Cap Equity R6	728.27K	0.61%	-
iShares Russell 2000 Value ETF	1.11M	0.57%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 20, 2026	Jones Keith Anthony	-	Buy	$6.93K
Aug 17, 2026	Jones Keith Anthony	-	Buy	$17.82K
May 19, 2026	Sebelius Kathleen	-	Buy	$50.00K
May 18, 2026	Constantino Michael T.	-	Buy	$9.84K
May 18, 2026	Sander Dale A.	CFO and Chief Corp. Dev. Off	Sell	$41.15K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	2	-
2026 Q2	2	2
2025 Q4	-	-
2025 Q3	-	6
2025 Q2	6	-

HUMA Ownership FAQ

Who Owns Humacyte?

Humacyte shareholders are primarily institutional investors at 37.70%, followed by 7.29% insiders and 55.01% retail investors. The average institutional ownership in Humacyte's industry, Biotech Stocks , is 379.01%, which Humacyte falls below.

Who owns the most shares of Humacyte?

Humacyte’s largest shareholders are Blackrock (7.14M shares, 6.60%), Vanguard group (8.42M shares, 5.32%), and Vanguard capital management (10.11M shares, 5.11%). Together, they hold 17.02% of Humacyte’s total shares outstanding.

Does Blackrock own Humacyte?

Yes, BlackRock owns 6.60% of Humacyte, totaling 7.14M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 34.27M$. In the last quarter, BlackRock increased its holdings by 2.35M shares, a 49.10% change.

Who is Humacyte’s biggest shareholder by percentage of total assets invested?

Lion point capital, lp is Humacyte’s biggest shareholder by percentage of total assets invested, with 2.43% of its assets in 650K Humacyte shares, valued at 507.26K$.

Who is the top mutual fund holder of Humacyte shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Humacyte shares, with 2.86% of its total shares outstanding invested in 7.72M Humacyte shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools